Welcome to our dedicated page for Estrella Immunopharma news (Ticker: ESLAW), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma Inc (ESLAW) is a clinical-stage biopharmaceutical company pioneering T-cell therapies targeting CD19 and CD22 antigens for cancer and autoimmune treatments. This news hub provides investors and researchers with essential updates on the company's scientific advancements and operational developments.
Access real-time announcements including clinical trial progress, research collaborations, and strategic milestones. Our curated collection features earnings reports, regulatory filings, and peer-reviewed study outcomes - all critical for evaluating ESLAW's position in the competitive immunotherapy landscape.
Key updates cover three focus areas: therapy development (ARTEMIS platform innovations), clinical research (trial phases and results), and strategic partnerships (academic/industry collaborations). Regular monitoring helps stakeholders track the company's progress from lab research to potential commercialization.
Bookmark this page for streamlined access to ESLAW's material disclosures. Combine our news feed with SEC filings and scientific publications for comprehensive analysis of this innovative biopharma enterprise.
Estrella Immunopharma (NASDAQ: ESLA) has successfully completed the first dose cohort in its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-Redirected ARTEMIS® T-cell therapy. The Data and Safety Monitoring Board has approved advancing to the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight.
The trial, targeting patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who failed multiple prior therapies, showed promising preliminary results. The first cohort demonstrated a favorable safety profile with no dose-limiting toxicities or treatment-related serious adverse events. Notably, tumor response was observed in all patients at Month 1.
The STARLIGHT-1 trial follows a standard 3+3 dose-escalation design, aiming to evaluate safety, tolerability, and preliminary efficacy of EB103 in adult patients with relapsed/refractory B-cell NHL.
Estrella Immunopharma (NASDAQ: ESLA) received a Buy rating with a $16.00 price target from D. Boral Capital. The analysis focuses on EB103's development in B-cell Non-Hodgkin's Lymphoma and the company's ARTEMIS® T-cell engineering platform, which mimics natural T-cell receptor mechanisms for a more regulated immune response.
The valuation model incorporates a 30% probability of success and a 30% discount rate, reflecting the early clinical development stage. EB103 is currently in Phase I/II trials for relapsed/refractory and high-risk blood cancers. The company has an engagement agreement with D. Boral Capital for investment banking services, including potential underwriting and placement agent roles.
Estrella Immunopharma (NASDAQ: ESLA) has reported a complete response in the first patient treated with EB103 CD19-Redirected ARTEMIS® T-cells in its STARLIGHT-1 Phase I/II clinical trial. The patient, diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms, achieved this response one month after treatment. Notably, no treatment-related serious adverse events were observed, despite the patient's high-risk profile.
Dr. Cheng Liu, CEO of Estrella, expressed cautious optimism about these early results, highlighting the company's goal to develop T-cell therapies that match or exceed the efficacy of current CAR-T therapies while improving safety. The STARLIGHT-1 trial aims to assess EB103's safety and determine the Recommended Phase II Dose in adult patients with relapsed/refractory B-cell NHL.
Estrella Immunopharma (NASDAQ: ESLA, ESLAW) has appointed Hong Zhang as Chairperson and Board member, expanding the board from five to six directors. This follows the company's recent milestone of dosing the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. Ms. Zhang brings over 25 years of financial and corporate strategy experience, having held key positions at Incinta Medical Group, Beijing Ocean Co-stone Capital Investment Management, and UOB Investment (China). CEO Dr. Cheng Liu, who previously served as Chairman, will continue as a board director.
FAQ
What is the current stock price of Estrella Immunopharma (ESLAW)?
